Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT07940790

A Single-center, Open-label, Non-randomized Pilot Study of add-on Olmesartan 20 mg or 40 mg Daily, With the Dose Chosen According to Blood Pressure at Enrollment as in Routine Practice, Over 9 Months in Patients With Type 2 Diabetes and Albuminuria Who Were Already Receiving an SGLT2i.

Conditions: Type 2 Diabetes Mellitus, Diabetic Kidney Disease, Albuminuria

Sex: All
Ages: 20 Years – 80 Years
Healthy volunteers: No
Phase: NA
Enrollment: 60
Sponsor: Tri-Service General Hospital (TSGH)

Location: Tri-Service General Hospital Taipei

Summary

This study evaluates the efficacy and safety of adding olmesartan to sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapy in patients with type 2 diabetes mellitus and persistent albuminuria. Participants receive olmesartan at a dose of either 20 mg or 40 mg daily in addition to their ongoing SGLT2i treatment. Changes in urinary albumin-to-creatinine ratio (UACR), renal function, and blood pressure are assessed over a 9-month follow-up period. The study aims to evaluate the potential additional renoprotective effects of olmesartan in patients with type 2 diabetes who continue to have albuminuria despite SGLT2i therapy.

Eligibility Criteria

Inclusion Criteria: * Type 2 diabetes mellitus. * Receiving sodium-glucose cotransporter-2 inhibitor therapy. * With persistent albuminuria * Willing and able to provide written informed consent. Exclusion Criteria: * Known hypersensitivity or history of severe adverse reactions to other angiotensin receptor blockers (ARBs). * Active liver disease or severe hepatic impairment (Aspartate transaminase \[AST\] \> 3 × ULN \[upper limit of normal\]; Alanine transaminase \[ALT\] \> 3 × ULN). * Moderate-to-severe renal impairment (estimated GFR \< 30 mL/min/1.73 m²). * Women who are pregnant or currently breastfeeding. * Judged by the study investigator to be unsuitable for participating (or continuing) in this trial.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07940790). StuddyBuddy aggregates publicly available trial information.